Comanche Biopharma has filed a notice of an exempt offering of securities to raise $75,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Comanche Biopharma is raising up to $75,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Scott Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Comanche Biopharma
Comanche is a preclinical biopharmaceutical company developing novel siRNA molecules for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining natural pregnancy and allowing for fetal maturation. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable. Our mission is to prevent or treat preeclampsia at its root cause.
To learn more about Comanche Biopharma, visit http://comanchebiopharma.com/
Contact:
Scott Johnson, Chief Executive Officer
617-206-3776
https://www.linkedin.com/in/t-scott-johnson-15038290/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.